Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico
Advances in Surgical Sciences
Volume 1, Issue 2, August 2013, Pages: 6-10
Received: Jul. 15, 2013; Published: Aug. 20, 2013
Views 3649      Downloads 181
Authors
Horacio Noé López-Basave, Department of SurgicalOncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Flavia Morales-Vásquez, Department of SurgicalOncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Juan M. Medina-Castro, Department of SurgicalOncology, Centro Oncologico Estatal,Instituto de Seguridad Social del Estado de México y Municipios (ISSEMYM), Toluca, Edo. de México, Mexico
Isaías Padilla-Mota, Department of SurgicalOncology, Centro Oncologico Estatal,Instituto de Seguridad Social del Estado de México y Municipios (ISSEMYM), Toluca, Edo. de México, Mexico
Juan M. Ruiz-Molina, Department of SurgicalOncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Article Tools
PDF
Follow on us
Abstract
Background: Ovarian cancer is a lethal tumor, 70% of which occurs in locally advanced stages. Despite its high initial response rate to chemotherapy, recurrence takes place in up to 90%. Prognosis of recurrent disease remains poor. In recent years, a new approach has been developed, combining a maximal cytoreductive effort with Hyperthermic intraperitoneal chemotherapy (HIPEC).Methods: We conducted a pilot study of 14 patients with recurrent ovarian cancer who were treated with Cytoreductive surgery (CRS) and HIPEC at the Mexico City-based National Cancer Institute of México (INCan) between January 2007 and January 2012.Results: There were 14 patients with recurrent ovarian cancer, including 13 with clinical stage IIIC and one with clinical stage CEIV due to retroperitoneal tumor with recurrence. Average age was 52 years (range, 20–72 years). Mortality and morbidity rates were 0 and 40%, respectively. Average surgical operative time was 7.5 h (range, 4.7–11 h). Average bleeding amounted to 1,171 mL (range, 100–3,700 mL).Overall median survival (OMS) was 14 months (range, 2–37 months). Peritoneal carcinomatosis index (PCI) showed eight patients with <20 and six with >20 points. Bleeding correlates with the PCI of >20 points. Performance status was a significant prognostic factor in patients with extensive peritoneal carcinomatosis (PCI, >20).Conclusions: Therapy combining CRS and HIPEC is feasible in selected patients with recurrent ovarian carcinoma with high morbidity. With ovarian cancer, novel therapies should be explored, one of which could be HIPEC.
Keywords
Cytoreductive Surgery, HIPEC, Recurrent Ovarian Cancer, Cisplatin
To cite this article
Horacio Noé López-Basave, Flavia Morales-Vásquez, Juan M. Medina-Castro, Isaías Padilla-Mota, Juan M. Ruiz-Molina, Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico, Advances in Surgical Sciences. Vol. 1, No. 2, 2013, pp. 6-10. doi: 10.11648/j.ass.20130102.11
References
[1]
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002.CA Cancer J Clin. 2005 Mar-Apr; 55 (2):74-108.
[2]
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB.Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst. 2004 Nov 17;96(22):1682-1691.
[3]
American Cancer Society. Cancer Facts &Figures 2012. Atlanta, GA, USA: American Cancer Society; 2012.
[4]
Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 (Suppl 1):S161-S192.
[5]
Di Giorgio A, Naticchioni E,Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with Hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008 July 15;113:315-325.
[6]
Piso P, Dahlke M-H, Loss M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer.World J Surg Oncol. (Abstract). 2004; 2:21. doi:10.1186/1477-7819-2-21.
[7]
Carrabin N, Mithieux F, Meeus P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.Bull Cancer.2010 April;97 (4):E23-32.
[8]
Sugarbaker PH.Peritonectomy procedures. AnnSurg 1995 January;221(1):29-42.
[9]
Kurman RJ, Shih LM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm.HumPathol. 2011 Jul;42(7):918-931.
[10]
Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. (Review). Cancer Treat Rev. 2001 Dec;27(6):365-374.
[11]
HelmCW.The role of hyperthermic intraperitoneal chemotherapy(HIPEC) in ovarian cancer. Oncologist. 2009 Jul;14(7):683-694.
[12]
Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol.2001;195:451-456.
[13]
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.
[14]
Deraco M, Baratti D, Kusamura S, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J SurgOncol. 2009 Sep 15;100(4):321-328. doi: 10. 1002/jso.21388.
[15]
Loggie BW, Sterchi JM, Rogers AT, et al. Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. Reg CancerTreat..1995;7(2):78-81.
[16]
Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. The role of cytoreductivesurgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON. 2011;16(1):74-79.
[17]
Deraco M, Kusamura S, Virzi S, et al. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy as upfront therapyforadvanced EOC: multi-institutionalphase II study. GynecolOncol. 2011;122(2):215-220.
[18]
Helm CW, Randall-Whitis L, Martin RS 3rd, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.GynecolOncol. 2007 Apr;105(1):90-96.
[19]
Sugarbaker PH (2005). Commentary. Reichman TW, et al.Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma.JSurgOncol.2005;90:56-58.
[20]
Zanon C, Clara R, Chiappino I, Bortolini M, et al Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.World J Surg. 2004 Oct;28(10):1040-1045.
[21]
Rufián S, Muñoz-Cásares FC, Briceño J, et al.Radical surgery peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J SurgOncol. 2006 Sep 15;94(4):316-324.
[22]
Cotte E, Glehen O, Mohamed F, LamyF,et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients.World J Surg. 2007 Sep;31(9):1813-1820.
[23]
Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum.Int J Gynecol Cancer. 2003 Nov-Dec;13(6):764-770.
[24]
Spiliotis JD, Rogdakis A, Vaxevanidou A, et al. Morbidity and mortality of cytoreductive surgery and hyperthermic ntraperitoneal chemotherapy in the management of peritoneal carcinomatosis. JBUON. 2009;14(2):259-264.
[25]
Fagotti A, Costantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. GynecolOncol. 2011;122(2):221-225.
[26]
Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori. 2001;87(3):120-126.
[27]
Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32(6):671-675.
[28]
Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer.2008;113(2):315-325.
[29]
Fagotti A, Paris I, Grimolizzi F, et al. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. GynecolOncol. 2009;113(3):335-340.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186